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Background: High mortality rates in ovarian cancer are largely a result of resistance to currently used
chemotherapies. Expanding therapies with a variety of drugs has the potential to reduce this high mortality rate.
Metformin and phenethyl isothiocyanate (PEITC) are both potentially useful in ovarian cancer, and they are
particularly attractive because of their safety.
Methods: Cell proliferation of each drug and drug combination was evaluated by hemacytometry with Trypan blue
exclusion or Sytox green staining for cell death. Levels of total and cleaved PARP were measured by Western blot.
General cellular and mitochondrial reactive oxygen species were measured by flow cytometry and live cell confocal
microscopy with the fluorescent dyes dihydroethidine and MitoSOX.
Results: Individually, metformin and PEITC each show inhibition of cell growth in multiple ovarian cancer cell lines.
Alone, PEITC was also able to induce apoptosis, whereas metformin was primarily growth inhibitory. Both total cellular
and mitochondrial reactive oxygen species were increased when treated with either metformin or PEITC. The growth
inhibitory effects of metformin were reversed by methyl succinate supplementation, suggesting complex I plays a role
in metformin's anti-cancer mechanism. PEITC's anti-cancer effect was reversed by N-acetyl-cysteine supplementation,
suggesting PEITC relies on reactive oxygen species generation to induce apoptosis. Metformin and PEITC together
showed a synergistic effect on ovarian cancer cell lines, including the cisplatin resistant A2780cis.
Conclusions: Here we show that when used in combination, these drugs are effective in both slowing cancer cell
growth and killing ovarian cancer cells in vitro. Furthermore, the combination of these drugs remains effective in
cisplatin resistant cell lines. Novel combinations such as metformin and PEITC show promise in expanding ovarian
cancer therapies and overcoming the high incidence of cisplatin resistant cancers.
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Ovarian cancer continues to have a disturbing discrep-
ancy in incidence to mortality rate. While ovarian cancer
trends as eighth in overall incidence among women in
the United States, ovarian cancer mortality is signifi-
cantly higher and ranks fifth in female cancer deaths.
The difference in incidence to mortality rates is a com-
bined result of poor ovarian cancer screening and rapid
development of resistance to current chemotherapeutics.
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distribution, and reproduction in any mediumspecific initial symptoms, and CA-125 and transvaginal
ultrasound provide no additional benefit in reducing
mortality [1]. Expanding available chemotherapies may
improve the long term survival of ovarian cancer
patients by overcoming the resistance to platinum based
therapies and providing alternate mechanisms for cancer
cell death. Metformin and PEITC have both been indi-
vidually identified as potential ovarian cancer therapies
[2-5]. This work examines the combination of metfor-
min and PEITC as a novel treatment combination.
The exact mechanisms for the anti-cancer effects of
both metformin and PEITC are not entirely clear. How-
ever, several groups have found both metformin andentral Ltd. This is an Open Access article distributed under the terms of the
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tron transport chain [6,7]. While cancer cells have an
altered metabolism that heavily utilizes glycolysis, even in
the presence of oxygen, mitochondrial oxidative metabol-
ism is still necessary to generate intermediates needed for
cell replication and reducing agents to deal with oxidative
stress. This potential inhibition of complexes in the elec-
tron transport chain may increase reactive oxygen species
(ROS) within the cell, especially in the mitochondria, lead-
ing to damage and eventually cancer cell death.
The mechanism of cisplatin resistance in ovarian can-
cer is not precisely known, but may be due to reduced
uptake [8]. Some research suggests cisplatin uptake is
dependent on the copper transporter CTR1 [9]. Metfor-
min is highly concentrated in cells, likely through OCT1
[10], and has not been found to be affected by changes
that occur in cisplatin resistant cell lines. PEITC is a
lipophilic compound that does not rely on an active
transporter and can directly cross the cell membrane.
When taken orally in milligram amounts, peak PEITC
plasma levels based on HPLC analysis were measured in
the low micromolar range [11].
After being associated with lower cancer incidence in
diabetic patients [12], metformin has been studied in a
variety of cancers as a potential therapy. In breast cancer
cells metformin has been found to induce cell death and
improve the efficacy of existing therapies [13,14]. Previous
research with metformin in ovarian cancer has suggested
that mechanisms in addition to AMPK activation are re-
sponsible for inhibition of cell growth [3]. Metformin's
partial inhibition of complex I, NADH dehydrogenase, has
been identified as an effect potentially upstream of AMPK
activation [7]. This mechanism is also interesting because
it may provide an AMPK independent pathway for met-
formin to damage cancer cells through ROS production
and mitochondrial damage.
PEITC gained interest as a potential anti-cancer agent
based on findings of lower cancer incidence in people
with diets high in cruciferous vegetables [15]. With
PEITC specifically, preclinical animal models also asso-
ciated the drug with decreased carcinogenesis [16,17].
Early studies of PEITC in transformed ovarian epithelial
cells also found ROS generation to mediate cell death
[5]. This ROS generation was later found to be a result
of complex III, cytochrome bc1 complex, inhibition in
colorectal cancer cells [6]. These drugs which work in al-
ternative pathways from cisplatin may provide additional
therapeutic options in ovarian cancer.
Methods
Reagents
Metformin, PEITC, cisplatin, and most other reagents
were purchased from Sigma Aldrich (St. Louis, MO). Tis-
sue culture media, DMEM and RPMI were purchasedfrom Thermo-Fisher Scientific (Waltham, MA). Fetal bo-
vine serum (FBS) was purchased from Atlanta Biologicals
(Atlanta, GA). Fluorescent dyes: MitoSOX, 2’,7’-dichloro-
dihydrofluorescein (DCF), dihydroethidine (DHE), dihy-
drorhodamine 123 (DHR), Sytox green, and MitoTracker
Green were all purchased from Invitrogen (Grand Island,
NY). Antibodies to detect AMPK, PARP, cleaved PARP
were purchased from Cell Signaling Technology (Beverly,
MA). Antibodies to detect MnSOD were purchased from
BD Pharmingen (San Diego, CA).
Cell culture
Cell lines were incubated in a 37 C, 5% CO2 humidified
chamber. OVCAR3, CAOV3, SKOV3, and PA-1 were
obtained from ATCC. A2780 and A2780cis were
received as a kind gift from Dr. Subhash Chauhan.
OVCAR3, CAOV3, SKOV3, and PA-1 were maintained
in DMEM supplemented with 10% fetal bovine serum,
100 units/mL penicillin, 100 μg/mL streptomycin, and
250 ng/mL amphotericin B. A2780 was maintained in
RPMI with 10% FBS, 100 units/mL penicillin/strepto-
mycin, and 250 ng/mL amphotericin B. A2780cis cells
were maintained in complete RPMI media supplemented
with 1 μM cisplatin every 3rd passage to maintain selec-
tion for cisplatin resistance.
Cell counting
Multiple methods were used in cell counting. For cells
counted by glass hemacytometer with Trypan blue exclu-
sion, adherent cells were harvested by trypsinization. For
live and dead cell counts, media was also collected and
added to the cell suspension. Cells were pelleted by centri-
fugation (200 x g) and each sample was resuspended in an
equal volume. Samples were then mixed with an equal
volume of 0.4% Trypan blue and counted using a glass
hemacytometer. Cells excluding Trypan blue were
counted as live, stained cells were counted as dead. Sytox
green (Invitrogen) fluorescent dye was also used for dead
cell analysis. In a 96-well plate format, cells were plated in
phenol red free media 24 hours prior to treatment with
drugs of interest. At desired time points, Sytox green dye
was added to wells at 1 μM final concentration and incu-
bated for 10 minutes to stain DNA of dead cells. Fluores-
cence was measured using a Spectramax M5 fluorescence
plate reader at excitation 485, emission 530, cutoff 515.
Total cell fluorescence was measured by adding Triton X-
100 at a final concentration of 0.1% to all wells, incubating
for 10 minutes, and remeasuring Sytox fluorescence.
Anchorage dependant colony formation assay
Cells were plated at 300–500 cells per 100 mm dish 24
hours before beginning treatment conditions. Cells were
allowed to grow for 7–10 days before fixation. Colonies
were fixed using 70% ethanol, and stained using 1%
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onies was obtained using image analysis software
(AlphaInnotech). Colonies were defined as a minimum
of 50 cells in a group.
Western blotting
Samples were harvested in an SDS based buffer, soni-
cated and heated before running. Proteins were sepa-
rated by SDS-PAGE and transferred to PVDF membrane
by semi-dry transfer apparatus. Antibodies for detection
of proteins of interest were diluted in blocking buffer,
5% BSA in TBST. Signal was detected using HRP-
conjugated secondary antibodies and Amersham ECL
prime detection reagent (GE healthcare). Exposures were
captured either by photographic film or CCD camera
imaging system (UVP).
Flow cytometry for oxidative stress
After varying treatment periods, adherent cell cultures
were detached with trypsin and transferred to culture
tubes as a cell suspension. Cells were then incubated with
fluorescent dyes to determine levels of oxidative stress
products. MitoSOX (Invitrogen) was used to measure
mitochondrial specific superoxide. Dihydroethidine (DHE)
was used to measure total cellular superoxide. Absorbance
was measured with the FL2 channel (Ex / Em) of an
Accuri C6 flow cytometer. Data was collected and ana-
lyzed using Cflow Plus software (BD-Accuri).
Live cell confocal microscopy
Cells were cultured on a chambered coverglass (Thermo
scientific) in phenol red free DMEM with 10% FBS. After
completing desired drug treatment courses, cells were
stained with dyes of interest in phenol red free DMEM
with 5% FBS. MitoSOX was used at 5 μM final concentra-
tion and MitoTracker green at 100 nM final concentra-
tion. Cells were incubated with dye for 15 minutes at 37 °
C, and then washed twice with PBS. Phenol free DMEM
with 5% FBS was used during live cell imaging. An Olym-
pus FV1000 imaging system on an Olympus IX81 inverted
microscope with heated 5% CO2 stage chamber was used
for image capture. Image processing and analysis was
completed using Olympus FluoView software.
Statistics
Error bars displayed are standard deviations. Compari-
son of two groups was done using a two-tailed
student’s t-test. Analysis of multiple groups was per-
formed by ANOVA or Chi-squared test using R, the
statistical computing program.
CalcuSyn (BioSoft) was used to calculate combination
index values for drug combinations. Drug combinations
were given at constant ratios and effect measured was
either cell death or cell growth inhibition.Results
Metformin is cytostatic, PEITC is cytotoxic in multiple
ovarian cancer lines
Across many human epithelial ovarian cancer cell lines,
metformin was found to significantly lower cell prolif-
eration (Figure 1A). This effect was greater over longer
treatment periods (Compare 48 hour treatment
Figure 1A and 24 hour treatment 5A below). Live cell
proliferation was measured using a glass hemacytometer
and Trypan blue exclusion. With drugs of interest that
target cellular metabolism, direct live cell counting using
a glass hemacytometer is preferred over assays such as
the MTT which rely on cellular respiration to indirectly
measure number of cells. In addition to inhibiting cell
growth, anchorage dependant colony formation was
strongly inhibited by metformin (Figure 1C and 1D). In
the cisplatin resistant cell line SKOV3, metformin was
still effective at preventing colony formation (Figure 1C).
When the same cell lines were treated with PEITC,
their growth was also significantly inhibited (Figure 1B).
While metformin is highly effective at reducing cell pro-
liferation, cell death is not induced. On the contrary,
PEITC was cytotoxic to many ovarian cancer cell lines
(Figure 2). Cell death induced by PEITC was dose
dependent and significantly higher than controls in the
low micromolar range. Examination of PARP showed a
shift from intact full length PARP to the cleaved form
when cells were treated with PEITC (Figure 3). This shift
suggests apoptosis as the primary cause of cell death for
PEITC. PARP cleavage was not observed in cells treated
with metformin over the same time period. This is
consistent with the results showing a lack of metformin-
induced cell death in the cell lines examined.
ROS is increased with both metformin and PEITC
Because previous research has found metformin to in-
hibit complex I and PEITC to inhibit complex III of the
mitochondrial electron transport chain, ROS levels were
examined as a potential mechanism for each drug's anti-
cancer effects. Inhibition of complex I increases the
aberrant flow of electrons to oxygen and creates super-
oxide within the mitochondrial matrix. Inhibition of
complex III also increases superoxide production, but
can generate these ROS species in either the cytosol or
mitochondria because of its position in the mitochon-
drial membrane [18]. When live cells were treated with
metformin or PEITC, they showed increased ROS as
measured by MitoSOX (Figure 4A). MitoSOX is an
ethidine based mitochondrial targeted probe that prefer-
entially reacts with superoxide to produce a fluorescent
product. Dihydroethidine (DHE) is a non-targeted ROS
detector and can assess total cellular oxidative stress. In
cells treated with metformin, fluorescence of DHE as
detected by flow cytometery was also increased
Figure 1 Individual effects of metformin and PEITC on ovarian cancer lines in vitro. A. Metformin growth inhibition of multiple human
ovarian cancer cell lines after 48 hour treatment with control (H2O vehicle) 8 mM metformin. B. PEITC growth inhibition of multiple human
ovarian cancer cell lines after 24 hour treatment with control (DMSO vehicle) or 5 μM PEITC. Both metformin and PEITC induce a significant
decrease in cell proliferation across all tested cell lines. Cell proliferation and growth inhibition was measured using hemacytometry with Trypan
blue exclusion. C. Anchorage dependant colony formation assay on cisplatin resistant SKOV3 line shows significantly fewer colonies in metformin
[5 mM] compared to cisplatin [5uM] treatment. D. In CAOV3, metformin is just as effective as cisplatin in reducing colony formation. * p< 0.01; #
p< 0.05; n.s. = not significant.
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fied mechanisms of ETC complex inhibition by both
metformin and PEITC results in an increase of ROS
within the cancer cell.
In order to determine the role of ROS in each drug's
effects on cell proliferation or apoptosis, ROS scavengingFigure 2 Individual cell death effects of metformin and PEITC. A. Metf
after 48 hours shows minimal cell death induction. B. PEITC [5 μM] induces
a 24 hour treatment. Cell death percentage was determined using hemacy
* p< 0.01.compounds were used. When the ROS scavenger N-
acetyl-L-cysteine was used to pretreat cancer cells before
addition PEITC, cell death induction by the drug was
completely reversed (Figure 5). This finding suggests
PEITC is heavily dependent on ROS production and oxi-
dative stress to induce apoptosis.ormin treatment [8 mM] on multiple human ovarian cancer cell lines
significant cell death of multiple human ovarian cancer cell lines after
tometry with Trypan blue exclusion to count both live and dead cells.
Figure 3 Cause of cell death for PEITC treated cells. PARP cleavage is increased by treatment with PEITC in multiple ovarian cancer cell lines,
indicating death by apoptosis. Western blot for full length and cleaved PARP after 48 hours of treatment is displayed. Blots are representative
images of band intensity. Bar graph represents cleaved PARP band intensity normalized to β-actin. * p< 0.01, # p< 0.05, n.s. = not significant.
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addition of a ROS scavenger, the effects of metformin
on cell proliferation are not strongly affected. This
may be due to metformin's general action of growth
inhibition versus PEITC's induction of apoptosis.
Metformin's complex mechanism, working through
several pathways may also play a role. In situations
where complex I inhibition does not produce high
amounts of ROS to damage a cancer cell's mitochon-
dria, metformin's action through AMPK and mTOR
may still allow growth inhibition to be achieved.
However, treatment of cells with methyl succinate
partially reversed the ability of metformin to inhibit
growth of PA-1 cells (Figure 6). Methyl succinate can
bypass electron transport through complex I because
it donates electrons directly to complex II of the
mitochondrial electron transport chain. These results
suggest inhibition of electron flow may be respon-
sible for some of metformin's growth inhibition
effects. As metformin concentration increases, the ef-
fect of methyl succinate is overcome, which is likely
a result of metformin-induced activities such as
AMPK activation.Metformin and PEITC combined are effective in a cisplatin
resistant cell line
The results above indicate that metformin and PEITC
function through different mechanisms and have different
consequences on the growth and survival of ovarian can-
cer cells. Therefore we hypothesized that the two drugs
would act synergistically when used in combination. In the
cell line CAOV3, combination therapy significantly
increased cell death over either drug individually
(Figure 7A). Attaining the high levels of cell death
observed for the combined drugs requires much higher
doses with the individual drugs. Furthermore, this combin-
ation continues to be effective in the cisplatin resistant cell
line A2780cis. Even high doses of cisplatin were not able
to match the cell death obtained through metformin and
PEITC combination in the A2780cis cell line (Figure 7B).
A Combination index (CI) is a value used to quantify the
degree of synergy or antagonism in drug combinations
[19]. As a general guideline, CI< 0.7 is synergistic, 0.7>CI
<1.2 is additive, and CI> 1.2 is antagonistic. When deter-
mined using CalcuSyn software (BioSoft), the metformin
and PEITC combination was found to be synergistic at
several effective doses in the cisplatin resistant line
Figure 5 NAC supplementation reverses PEITC cell death. A. The effect of NAC supplementation on control (DMSO vehicle), metformin
[5 mM], and PEITC [5 μM] growth inhibitory effects on PA-1 cell line after 24 hours. Metformin is relatively unaffected by the addition of NAC,
while PEITC's growth inhibition is significantly reduced. B. The dead cell percent of PA-1 cells treated with control (DMSO vehicle), metformin, or
PEITC treatment with and without NAC pre treatment. Metformin alone does not induce high amounts of cell death with or without NAC. PEITC's
cell death is strongly reduced to levels similar to control when pretreated with NAC to act as an ROS scavenger. * p< 0.01; n.s. = not significant.
Figure 4 Mitochondrial reactive oxygen species (ROS) increased with metformin and PEITC treatment. A. Live cell confocal image of
SKOV3 cells treated for 24 hours. MitoSOX, a mitochondrial specific superoxide detector, exhibits increased fluorescence in metformin and PEITC
treated cells comparison to control treated cells. B. Mean fluorescence intensity from dihydroethidium (DHE) used to detect total cellular ROS. Cell
lines were treated for 24 hours with or without metformin [8 mM] and DHE intensity was measured by flow cytometry.
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Figure 6 Methyl succinate partially reverses metformin's
effects. When 12.5 mM methyl succinate is added to complete
growth media, the 48 hour growth inhibition effects of metformin
on PA-1 are reduced. Methyl succinate serves as an alternate energy
source to glucose that bypasses complex I in the electron transport
chain. Metformin at higher doses can overcome the reversal of
growth inhibition provided by methyl succinate. * p< 0.01.
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closer the CI is to 0. With a CI of 0.00015 at ED50 metfor-
min and PEITC doses, the combination is highly synergis-
tic and increases with higher ED combinations. In this cell
line, cisplatin remains ineffective at inducing cell death at
doses as high as 33 μM or 10 μg/mL.
Discussion
Expanding ovarian cancer therapies to include com-
pounds such as metformin and PEITC is attractive forFigure 7 Combination of metformin and PEITC. A. Combination of low
cell death after 72 hours compared to either drug individually. Combinatio
the cisplatin resistant ovarian cancer line A2780cis, metformin and PEITC w
significantly increased when metformin and PEITC are given together. Cisp
Combination index (CI) values for A2780cis calculated using CalcuSyn softw
greater synergy as the value approaches zero. Metformin and PEITC are syn
to control treatment.multiple reasons. Metformin has a broad safety profile,
and while the mechanism is not exactly known, a tre-
mendous amount of patient dosage data exists. The risk
for lactic acidosis in metformin is minimal, with cases
only commonly occurring with coexisting kidney dys-
function [20]. Similarly, PEITC's dosage safety can be
partially inferred from cruciferous vegetable intake. A
study of a defined watercress diet showed significant up-
take of PEITC in humans [21]. A current phase I trial of
PEITC in leukemia patients will further clarify safety and
dosing.
Metformin's complex mechanisms of action may pro-
vide many difficulties to cancer cells attempting to coun-
ter its actions. Because metformin likely acts through
multiple pathways, a cancer cell may be able to respond
to the stress of one change, but still be affected by other
alterations. Metformin's resistance to a variety of ROS
scavengers, propyl gallate, butylated hydroxyanisole,
Mito-TEMPO (data not shown) shows that metformin is
not reliant on ROS production to inhibit cancer cell
growth despite its actions on complex I. Still, complex I
inhibition partially contributes to the cell inhibition as
shown through the methyl succinate supplementation
experiment. The methyl succinate prevention of metfor-
min’s effect was diminished as metformin dose increased,
suggesting metformin acts through multiple pathways as
it accumulates within the cell. Higher doses of metformin
may act through AMPK pathway activation through a still
unknown exact mechanism. Likely, metformin's cellular
effects are a combination of AMPK pathway activationdoses of metformin and PEITC on CAOV3 show an improved effect on
n can reduce doses necessary to achieve high levels of cell death. B. In
ork synergistically and are more effective than cisplatin. Cell death is
latin, even at higher doses, is unable to produce similar cell death. C.
are. CI values below 1 are considered synergistic combinations, with
ergistic at equal ratio effective doses (ED). * p< 0.01 when compared
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tial inhibition increasing ROS.
Relevant dosing for metformin in vitro remains unclear.
Most groups work in the low millimolar range, from 1–
20 mM [3,22,23]. While this seems initially unattainable
in vivo, metformin is not metabolized and has been found
to be highly concentrated with the cells, especially within
mitochondria [7]. Moreover, these concentrations are ne-
cessary for in vitro work to mimic the effects observed
with in vivo studies where approved diabetic metformin
doses have been used. Thus, in order to achieve the con-
centrated cellular metformin levels and study the potential
changes that occur in vivo over longer periods of treat-
ment, high doses over short time courses must be used
in vitro.
While PEITC does not have the long historical use in
humans that metformin has, its general safety can be in-
ferred from diets high in cruciferous vegetables. Also,
similar to metformin, PEITC has been associated with
cancer prevention in several cohort studies [15,24].
Although PEITC is more effective at inducing cancer
apoptosis, it is also more simply reversed by increasing
ROS scavengers. Metformin's enhancement of PEITC
could be due in part to depletion of reducing agents[25]
needed to handle the ROS stress induced by PEITC.
Additionally, metformin may synergize with PEITC
through inhibition of complex I to provide extra mito-
chondrial oxidative stress, shifting the ROS balance
towards cell death.
Additional therapies that utilize different mechanisms
than cisplatin are especially attractive for ovarian cancer.
The combination therapy of metformin and PEITC is
interesting because of its effectiveness despite cisplatin
resistance. Additional work is warranted to determine if
this synergy is maintained with in vivo models. Current
data suggests metformin and PEITC as a combination
treatment have potential as a novel ovarian cancer
therapy.Conclusions
Complex I inhibition is partially involved in metformin's
growth inhibition of ovarian cancer, possibly by increas-
ing ROS and sensitizing cancer to additional oxidative
stress. PEITC induces ovarian cancer cell death by in-
creasing ROS. When given together, metformin and
PEITC show a synergistic increase in cell death in sev-
eral ovarian cancer cell lines, including cisplatin resistant
A2780cis cell line. This novel combination may be useful
in combating the high mortality of cisplatin resistant
ovarian cancers.
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